extension will bring the due date to April 1, 1994, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.18 from Arnold, White & Durkee Deposit Account No. 01-2508/CADL:002/PAR.

AMENDMENTS

In the Claims:

Please cancel claim 18, and amend claims 19 and 47 as follows:

19. (amended) A method for inducing or enhancing in a subject the production of antibodies reactive with tumor cells in the subject comprising administering an effective amount of the [vaccine] antigen composition of claim [18] 47.

47. (amended) An antigen composition [vaccine] comprising [a purified polypeptide subunit of] Urinary Tumor Associated Antigen [having] (UTAA) having an isoelectric point of about 6.1 and an apparent molecular weight of approximately 590-620 kD under non-reducing conditions; and after reduction by β-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis, the UTAA exhibits a polypeptide subunit having a molecular weight of about 90 to 100 kD, [and a pharmaceutically

acceptable carrier] the UTAA being at least 0.6% of the total protein content of the composition.

Please add the following new claims, claims 48-60:

-- 48. The antigen composition of claim 47, wherein the UTAA comprises about 0.6% of the total protein content of the composition.

49. The antigen composition of claim 47, wherein the UTAA is purified such that upon SDS-PAGE and silver staining, the composition is shown to consist essentially of four bands having an approximate apparent molecular weight of 138, 90, 50 and 25 kD.

50. The antigen composition of claim 47, wherein the UTAA is purified such that upon SDS-PAGE and staining, the composition is shown to consist essentially of three bands having an approximate molecular weight of 150, 90 and 45 kD.

51. The antigen composition of any one of claims 47 through 50, further defined as including a pharmaceutically acceptable carrier.

52. An antigen composition comprising Urinary Tumor Associated Antigen (UTAA) shown to have, after reduction by β-

mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis, a polypeptide subunit exhibiting a molecular weight of about 90 to 100 kD, the antigen composition further including at least two antigens selected from the group consisting of GM-2, GD-2, Fetal Antigen, and Melanoma-Tumor Associated Antigen (MTAA), said composition further defined as being pharmaceutically acceptable.

53. The antigen composition of claim 52, further defined as including at least three antigens selected from the group consisting of GM-2, GD-2, Fetal Antigen, and MTAA.

54. The antigen composition of claim 53, further defined as including each of GM-2, GD-2, Fetal Antigen, and MTAA.

55. The antigen composition of claim 54, wherein the composition is further defined as including a mixture of tumor cells and wherein at least a portion of the UTAA, GM-2, GD-2, Fetal Antigen and MTAA are contributed by the tumor cells, wherein said antigens are present in amounts effective to promote a cytotoxic or cytostatic effect upon administration of the composition to a cancer patient.

56. The antigen composition of claim 55, wherein the tumor cells include live, irradiated tumor cells.